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Introduction: Esmolol may efficiently reduce heart rate (HR) and decrease mortality during septic shock. An
improvement of microcirculation dissociated from its macrocirculatory effect may a role. The present study investigated
the effect of esmolol on gut and sublingual microcirculation in a resuscitated piglet model of septic shock.
Methods: Fourteen piglets, anesthetized and mechanically ventilated, received a suspension of live Pseudomonas
aeruginosa. They were randomly assigned to two groups: the esmolol (E) group received an infusion of esmolol, started
at 7.5 μg⋅kg−1⋅min−1, and progressively increased to achieve a HR below 90 beats⋅min−1. The control (C) group
received an infusion of Ringer’s lactate solution. HR, mean arterial pressure (MAP), cardiac index (CI), stroke index (SI),
systemic vascular resistance (SVR), arterio-venous blood gas and lactate were recorded. Oxygen consumption (VO2),
delivery (DO2) and peripheral extraction (O2ER) were computed. Following an ileostomy, a laser Doppler probe was
applied on ileal mucosa to monitor gut microcirculatory laser Doppler flow (GMLDF). Videomicroscopy was also used
on ileal mucosa and sublingual areas to evaluate mean flow index (MFI), heterogeneity, ratio of perfused villi and
proportion of perfused vessels. Resuscitation maneuvers were performed following a defined algorithm.
Results: Bacterial infusion induced a significant alteration of the gut microcirculation with an increase in HR. Esmolol
produced a significant time/group effect with a decrease in HR (P <0.004) and an increase in SVR (P <0.004). Time/
group effect was not significant for CI and MAP, but there was a clear trend toward a decrease in CI and MAP in the E
group. Time/group effect was not significant for SI, O2ER, DO2, VO2, GMLDF and lactate. A significant time/group effect
of ileal microcirculation was found with a lower ileal villi perfusion (P <0.025) in the C group, and a trend toward a
better MFI in the E group. No difference between both groups was found regarding microcirculatory parameters in the
sublingual area.
Conclusions: Esmolol provided a maintenance of microcirculation during sepsis despite its negative effects on
macrocirculation. Some parameters even showed a trend toward an improvement of the microcirculation in the gut
area in the esmolol group.Introduction
Esmolol is an ultrashort-acting beta-blocker that has
been reported as an efficient treatment to decrease heart
rate (HR) during septic shock; its use has been associ-
ated with reduced mortality in a recent study [1]. Des-
pite its seemingly counterintuitive concept, this trial has
confirmed a long preclinical and clinical suspicion of po-
tential interest for the use of beta-blockers during sepsis
in various animal models [2, 3], and in non-randomized* Correspondence: matthias.jl@gmail.com
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creativecommons.org/publicdomain/zero/1.0/study published more than four decades ago [4]. These
results need further confirmation, as beta-blockade can
be deleterious, especially in a context of circulatory fail-
ure where sympathetic blockade may precipitate a fatal
outcome. In perioperative care, promising results [5]
were not translated into survival benefit in a larger trial
[6]. A better understanding of the hemodynamic effects
of esmolol could permit a better timing for the initiation
and to monitor treatment or to assess the eligibility of
patients for this therapeutic strategy. Esmolol has been
described to reduce cardiac index (CI) score, which
raises the question of its immediate effect on microcir-
culation, particularly for the splanchnic area where earlyAccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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failure. Besides, esmolol has a vasodilatory effect, resulting
in coronary microcirculatory recruitment [7, 8]. The
mechanism of this vascular effect is not univocal, but the
reduction of endothelial shear stress [9] and subsequent
activation of endothelial NO synthase [10] may play a role.
Esmolol has been described to enhance microcircula-
tory failure during sepsis [11]. However, in the study
aforementioned, esmolol was administered many hours
after the onset of sepsis, with no control group. More-
over, microcirculation was evaluated in the sublingual
area but not in the gut area, as this area can hardly be
assessed in a clinical setting. As gut and sublingual
microcirculations can be uncoupled [11], and since gut
barrier preservation has been described as a potential
mechanism of action for beta-blockers [12], there is a
need to evaluate both gut and sublingual microcircula-
tory during esmolol treatment in patients in critical con-
dition. The aim of our study was to evaluate the effects
of a short-acting beta-blocker at the early stages of sepsis
on gut and sublingual microcirculation in a piglet model
of septic shock. The primary endpoint was the effect of
esmolol on gut microcirculation, evaluated by videomi-
croscopy. The secondary endpoint was the effect of
esmolol on sublingual microcirculation, macrocircula-
tion, oxygen metabolism and lactate.
Materials and methods
Animal preparation
The study was approved by our local ethical board for
animal research and care (Vet Agro Sup, Marcy l’Etoile,
France, authorization number: 1252) in accordance with
European regulations (Directive EU 86/609). A total
of 14 healthy female piglets, weighing between 25 and
40 kg and two to three-months-old, were selected.
At 12 h before the beginning of the experimental
phase solid food was withdrawn, while access to water
was still allowed. After sedation with an intramuscular
administration of tiletamine/zolazepam (Zoletil 100, 100
mg⋅mL−1, Virbac, Carros, France), 3.0 mg⋅kg−1 and
morphine 0.2 mg⋅kg−1, induction was carried out with an
intravenous administration of propofol (PropoFlo 10 mg/
mL, Axience, Pantin, France) 4.0 mg⋅kg−1, and maintained
with isoflurane (Vetflurane, Virbac Carros France) given to
effect in 30 % oxygen, morphine (0.1 mg⋅kg−1⋅h−1) and
cisatracurium (0.15 mg ⋅kg−1⋅h−1).
Animals were orotracheally intubated and mechanically
ventilated. A pulse oximeter was placed on the tongue to
continuously measure hemoglobin saturation (SpO2) and
HR. An electrocardiogram continuously monitored the
heart by means of three electrodes placed on the thorax of
the animals. Several catheters were surgically inserted after
inguinal incision and lateral cervicotomy. An arterial cath-
eter was inserted into the right femoral artery for systemicarterial pressure (MAP) measurement. A central venous
catheter was inserted in the femoral vein for fluid and
drug administration and central venous pressure (CVP)
measurement. A pulmonary arterial catheter (Edwards
Life science® catheter, Irvine, USA) was inserted in the
right jugular vein for mean pulmonary arterial pressure
(MPAP), pulmonary capillary wedge pressure and cardiac
(CO) output measurements. The suitable location of the
catheter tip was determined by the characteristic of the
pressure curve. An ileostomy was performed to allow po-
sitioning of a laser Doppler probe (Perimed Instrument,
Järfälla-Stockholm, Sweden) fixed on a balloon to enable a
contact between the probe and the mucosa. Multiple
videomicroscopy samples were carried out on the stoma
site. The abdomen and the neck wounds were then
sutured (PDS II, Ethicon, Issy-les-Moulineaux, France).
Blood samples were analyzed with a blood gas analyzer
(ABL90 Flex, Radiometer, Neuilly-Plaisance, France).
Experimental protocol
The experimental procedure is detailed in Fig. 1. After a
baseline period of 60 min, every piglet received an infusion
of Pseudomonas aeruginosa bacteria (Laboratoire de micro-
biologie du groupe hospitalier est, Hospice civil de lyon.
Bron , France) (5 × 108 colony forming unit (CFU)⋅mL−1
perfused at 0.3 mL⋅20 kg−1⋅min−1). The systolic pulmonary
arterial pressure (SPAP) was monitored. When SPAP
reached 45 mmHg, the bacterial infusion was stopped to
limit the right ventricular afterload and avoid any right
heart dysfunction. The goal was to obtain a reproducible
hyperdynamic septic shock as originally described [13, 14].
After initiation of resuscitation and hemodynamic
stabilization, animals were randomly assigned to two
groups: esmolol group (E) and control group (C). Animals
of the control group (n = 6) received an infusion of
Ringer’s lactate solution alone; those of the E group (n = 6)
also received an infusion of esmolol.
Esmolol was started at 7.5 μg⋅kg−1⋅min−1 (Baxter,
Maurepas, France), and progressively increased to decrease
HR to between 80 and 90 beats⋅min−1. Intravenous Ringer’s
lactate (Aguettant, Lyon, France) was administered during
the experiment at a basal rate of 10 mL⋅kg−1⋅h−1. Resuscita-
tion procedures were performed as follows: objectives were
to maintain MAP above 60 mmHg, venous saturation in
oxygen (SvO2) above 70 % and CI above 80 % of its basal
value. A fluid load of 250 mL of Ringer’s lactate solution
was administered initially to evaluate fluid responsiveness;
in case of absence of fluid response, norepinephrine
(if the MAP objective were not fulfilled) and/or milrinone
(if the CI objective was not achieved and if there
was no fluid responsiveness) were used. The initial
dose of norepinephrine (Renaudin, Itxassou, France)
was 0.04 μg⋅kg−1⋅min−1. The initial dose of milrinone
(Sanofi, Paris, France) was 0.375 μg⋅kg−1⋅min−1, and could
Fig. 1 Study design. After the stabilization period, animals received an intravenous infusion at T 0 min of Pseudomonas aeruginosa, 0.3 mL⋅20 kg−1⋅min−1.
At the onset of shock, resuscitation was started until stabilization (T stab), around 90 min after T 0 min. Animals were then randomized to receive esmolol
in the E group; esmolol was started (or isotonic saline (IS) in the C group) at 7.5 μg⋅kg−1⋅min−1 and increased until HR target (<90 min−1) was reached. The
experiment was ended after 300 min. A-V Blood Gas, arterio-venous blood gas; CI, cardiac index; CVP, central venous pressure; HR, heart rate; MAP, systemic
mean arterial blood pressure; MPAP, mean pulmonary arterial blood pressure; SpO2, pulsed oxygen saturation
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citation goals. At the end of the experimental time, animals
were killed using embutramide 0,3 ml/kg of a mixture of
embutramide, mebezonium and tetracaine T61 (200mg
ofembutramide, 26.92 mg of mebezonium and 4.39 mg
of tetracaïne per ml), Intervet, Beaucouze, France.
Bacterial preparation
A P. aeruginosa reference strain (ATCC 27853) was used
to induce septic shock. This strain was kept in a glycero-
lized heart/brain broth at −80 °C at the microbiology
laboratory (Laboratoire de Bactériologie du Centre de
Biologie et Pathologie Est, Hospices Civils de Lyon,
France). At 48 h before the experiment, two subcultures
were systematically performed to avoid any variation of
the reference strain. The suspension was kept in a re-
frigerator, ready for use less than two hours before the
administration into the piglets. To check the inoculum
concentration, two dilutions of bacteria suspension were
streaked on MH agar plates by Spiral instrument (AES/
bioMérieux, Marcy l’Etoile, France). These plates were
read after overnight incubation at 37 °C and compared
to nomogram of the Spiral® system to obtain the concen-
tration of bacteria suspension.
Data collection
HR, MAP, MPAP, CVP and, SpO2 were continuously
monitored. Cardiac output was measured every 30 min
and assessed three times by thermodilution technique
with 10 mL of cold solute injected via the pulmonary arter-
ial catheter. Arterial and venous blood gases were analyzed
every 60 min. Standard formula were used to compute
CI (L⋅min−1/⋅m−2), stroke index ((SI) mL⋅min−1⋅m−2),
systemic vascular resistance (SVR), pulmonary vascular
resistance ((PVR) dyn⋅s⋅cm−5⋅m−2), oxygen delivery ((DO2)
L⋅min−1⋅m−2) and consumption ((VO2) L⋅min−1⋅m−2).This enabled us to evaluate DO2/VO2 dependency by cal-
culating the correlation coefficient and oxygen extraction
ratio ((O2ER) %). Body surface area was calculated as
previously described [15].
The laser Doppler probe provided a signal of gut perfu-
sion named gut microcirculatory laser Doppler flow
(GMLDF). Videomicroscopy measurements of the sublin-
gual and gut microcirculation were obtained at T-60 min,
T 60 min (before bacterial injection, after bacterial injec-
tion and before esmolol administration) and T 270 min
(after esmolol administration) using a sidestream dark-
field (SDF) imaging device (Microscan, Microvision med-
ical, Amsterdam, The Netherlands) with a × 5 lens. Images
of the microcirculation were obtained for the ileal mucosa
through the ileostomy, and for the sublingual area. The
camera was applied without pressure, after removal of se-
cretions. Five sequences of five to 20 s each, from different
areas were recorded. A blinded investigator (MJL) per-
formed the semi-quantitative analysis of the sequences.
For the sublingual area, only vessels that crossed one of
the nine lines used to assess the De Backer score were
considered and scored as perfused or not, enabling calcu-
lation of the proportion of total perfused vessels ((PPV
total) %), small vessels perfused ((PPV small vessels) %)
and other vessels perfused ((PPV other vessels) %). Small
vessels were defined as a diameter smaller than 20 μm.
Other vessels were defined as a diameter larger than
20 μm. Microvascular flow was qualitatively evaluated
(from 0 to 3) for each of the four quadrants and each site;
microvascular mean flow index (MFI) was calculated by
using an ordinal scale with 0 meaning no flow, 1 an inter-
mittent flow, 2 a sluggish flow and 3 a normal flow [16, 17].
Heterogeneity index was calculated as previously de-
scribed [18]: an absolute change of 10 % in the PPV small
vessels was considered as clinically significant [19]. For in-
testinal area, the SDF camera’s objective was inserted
Table 1 Effect of bacterial infusion on hemodynamic and
metabolic parameters
–T-60 min T 60 min P value
Hemodynamic
HR (min−1) 97 (90 - 103) 117 (104 - 136) 0.007
MAP (mmHg) 64.9 (57.9 - 71.4) 71.2 (65.8 - 74.5) 0.106
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edge of the stoma, with a slight angulation as previously
described [20]. Heterogeneity index was calculated as the
difference between the highest and lowest MFI, divided by
the mean MFI of all sites at a single time point. PV was
estimated as the percentage of perfused villi divided by the
total number of villi or crypts times 100 % [16].MPAP (mmHg) 16.2 (14.9 - 19.1) 35.9 (31.5 - 38.8) 0.002
PCWP (mmHg) 7.6 (5.5 - 10.5) 8.6 (6.6 - 11.0) 0.307
CVP (mmHg) 9.9 (8.3 - 11.4) 11.3 (7.9 - 12.8) 1
CI (L⋅min−1⋅m−2) 2.4 (2.2 - 2.7) 2.9 (1.9 - 3.02) 0.62
SI (mL⋅m−2) 24.6 (23.4 - 27.3) 21.1 (18.0 - 27.8) 0.151
SVR (dyn⋅s⋅cm5⋅m−2) 2,458 (1,943 - 2,604) 2,344 (1,787 - 2,869) 0.577
PVR (dyn⋅s⋅cm5⋅m−2) 161.6 (149.3 - 191) 358.7 (314.9 - 388.8) 0.002
Metabolic
Lactate (mmol⋅L−1) 2.1 (1.8 - 2.8) 1.7 (1.4 - 2.8) 0.045
O2ER (%) 14.0 (8.9 - 19.1) 14.1 (11.3 - 15.8) 0.432
O2ER/CI 5.5 (3.5 - 7.4) 4.8 (2.9 - 6.4) 0.622
PaO2/FiO2 (mmHg) 327.8 (253.3 - 436.4) 385.2 (240.4 - 422.3) 0.470
Gut microcirculation
Videomicroscopy
MFI of the gut 2.7 (2.5 - 2.9) 1.56 (1.25 - 1.75) 0.003
Heterogeneity index
of the gut (%)
17.7 (4.7 - 33.4) 61.9 (27.5 - 72.3) <0.001
Ratio of perfused villi (%) 94.2 (90.0 - 97.7) 68.1 (59.0 - 76.5) 0.005
laser Doppler flow
GMLDF (ua) 154.2 (85.9 - 699.6) 130.7 (80.15 - 674.7) 1
GMLDF variation 1.04 (0.87 - 1.08) 0.92 (0.85 - 1.18) 0.677
Sublingual microcirculationStatistical analysis
Statistical analysis was performed with R software (R-
project, GNU GPL.) [21]. We used several packages of
the CRAN R project and computed descriptive statistics
for all data [22]. We used a Kolmogorov-Smirnov test to
check the normality of variables distribution. If the dis-
tribution was not normal, data were expressed as median
and interquartile range (25th to 75th percentiles) for
every variable, as appropriate. We used an analysis of
variance (ANOVA) test with repeated measures to detect
if there was any effect of time or group on the different
variables. Our data were not normally distributed, but
we checked that they were close to a normal distribution
on the frequency histogram, as ANOVA is not very sen-
sitive to moderate deviations from normality [23–25].
The Mann–Whitney U test and Wilcoxon test were per-
formed as appropriate. If data were too different at base-
line, data were expressed as variations from baseline and
expressed in percentage of variation from baseline.
Spearman’s correlations were used to evaluate the rela-
tionship between hemodynamic and microcirculation
variables. Statistical significance was defined as a P value
lower than 0.05.TVD (n⋅mm) 17.7 (15.8 - 18.4) 11.7 (11.2 - 12.9) 0.021
MFI 2.8 (2.7 - 2.9) 2.2 (2.1 - 2.3) <0.001
MFI small vessels 2.7 (2.5 - 2.9) 1.6 (1.4 - 1.8) 0.003
MFI other vessels 3.0 (2.9 - 3.0) 2.8 (2.8 - 2.9) 0.036
Heterogeneity index (%) 13.2 (4.4 - 24.2) 64.6 (34.4 - 84.2) <0.001
PPV other vessels 99.7 (96.2 - 100) 96.03 (75.6 - 100) 0.262
PPV small vessels 91.9 (88.2 - 95.2) 64.6 (51.9 - 68.1) <0.001
Hemodynamic parameters before and after the onset of sepsis but before
esmolol administration. Wilcoxon test were performed to compare variables
before and after sepsis. HR: heart rate, MAP: systemic mean arterial blood
pressure, MPAP: mean pulmonary mean arterial blood pressure, PCWP:
pulmonary capillary wedge pressure, CVP: Central venous pressure, SI: stroke
index computed as CI/HR, SVR: systemic vascular resistance, CI: cardiac index,
PVR: pulmonary vascular resistance, O2ER: oxygen extraction ratio, FiO2:
fraction of inspired oxygen, GMLDF: gut microcirculatory laser Doppler flow,
TVD: total vessels density, MFI: microvascular flow index. Ratio of perfused villi:
proportion of perfused villi, PPV: proportion of perfused vessels, small vessels:
vessels with a diameter under 20 μm, Other vessels: vessels with a diameter
above 20 μm, mmHg: millimeters of mercury, mmol⋅L−1: millimoles⋅Liter,
PaO2: arterial partial pressure of oxygenResults
A total of 14 piglets were initially selected, but two
piglets died before randomization and were withdrawn
from the study. The analysis was finally composed of 12
pigs: six in the E group and six in the C group, weighing
a mean of 37.3 kg (range: 35.6 to 39.2), with a mean of
0.79 m2 (range: 0.77 to 0.82 m2) body surface area.
Weight of the piglets appeared relatively similar between
groups: the mean weight in the E group was 36.5 kg
(range: 36.0 to 37.3 kg) and the mean weight in the C
group was 38.2 kg (range: 34.6.6 to 40.0 kg); however,
we noticed a significant difference between both groups
(Wilcoxon test, P = 0.047). Similarly, mean body surface
areas were 0.78 m2 (range: 0.77 to 0.79 m2) in the E
group and 0.80 m2 (0.75 to 0.83 m2) in the C group
(P = 0.047). The maximal limit of SPAP (45 mmHg
threshold to stop bacterial infusion) was reached within a
mean of 27.0 min (range: 23.5 to 41.0 min) in the C group
and 37.0 min (range: 34.0 to 40.0 min) in the E group.
These durations of bacterial administration were not
significantly different between both groups (P = 0.410).Effect of bacterial infusion on microcirculation and
macrocirculation in both groups
Hemodynamic effects of P. aeruginosa infusion on micro
and macrocirculation are shown in Table 1. Data were
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lets. Resuscitation maneuvers had already started for every
piglet at T 60, but esmolol administration had not started
at that time. A significant increase in HR and a trend to-
wards a significant increase in MAP and CI were observed.
In parallel, a significant alteration of microcirculation
in the gut area was observed with a significant decrease
in MFI and PV, and a significant increase in heterogen-
eity. An alteration of sublingual microcirculation was
also found with a significant decrease in total vessels
density (TVD), MFI, heterogeneity index and PPV small
vessels (Table 1). No significant difference between groups
was found at that time.
Effect of esmolol on macrocirculation
Hemodynamic stabilization was obtained between T
60 min and T 180 min (prerequisite for esmolol injection).
Results are shown in Fig. 2. We observed a significant
time/group effect with a decrease in HR as well as a trend
toward a decrease in MAP and in CI. We observed a sig-
nificant increase in SVR in the esmolol group. SI was not
significantly different between both groups. We did not
observe any significant time/group effect for the evolution
of PVR (Fig. 2).
Metabolic effect of esmolol
Results of the metabolic effect of esmolol are shown in
Fig. 3. DO2 and VO2 did not vary significantly in the EFig. 2 Evolution of hemodynamic variables during the experiment. T-60 m
injection. Esmolol is started and hemodynamic stabilization occurs betwee
concluded at T 300 min. ANOVA were performed for each parameter: (a) H
P = 0.004; (b) SI, group effect P = 0.222, time effect P = 0.050, time/group ef
time/group effect P = 0.339; (d) MAP, group effect P = 0.099, time effect P =
time effect P = 0.023, time/group effect P = 0.004; HR, heart rate; CI, cardiac
blood pressure; SI, stroke index computed as CI/HR; SVR, systemic vasculargroup. There was a manifest trend toward a significant
difference between E and C group for the DO2. No
significant difference between groups was observed for
lactate. There was no DO2/VO2 dependency, as attested
by the poor correlation between DO2 and VO2 in both
groups (rDO2/VO2 = 0.367; P = 0.001). This correlation
was not significant in the E group (DO2/VO2 = 0.263;
P = 0.093). Median value of SvO2 remained between 77
and 85 % in each group throughout the experiment. No
significant time effect (P = 0.446) or time/group effect
(P = 0.119) was found, while a significant group effect
was found (P = 0.029).
Effect of esmolol on microcirculation
The effects of esmolol on gut microcirculation are
detailed in Fig. 4. Regarding gut area, a significant
difference in evolution of PV was found between both
groups (time/group effect, P = 0.025) with a non signifi-
cant increase in MFI for the E group (time/group effect,
P = 0.2) (Table 2 and Fig. 4). Concerning sublingual area,
MFI was not significantly different between groups. No
significant effect of esmolol on sublingual microcircula-
tion was observed (time/group effect, P = 0.08). GMLDF
did not significantly differ between both groups. We ob-
served a dissociation between the gut and sublingual
microcirculation as suggested by the moderate correlation
between the parameters of the two localizations (rMFI
small vessels-MFI gut = 0.608, P = 0,001; r heterogeneityin is the beginning of stabilization; T 0 min is the time of bacterial
n T 60 and T 180 min after resuscitation is started, and the experiment
R, group effect P <0.001, time effect P = 0.223, time/group effect
fect P = 0.404; (c) CI, group effect P = 0.006, time effect P = 0.508,
0.042, time/group effect P = 0.051; (e) SVR, group effect P = 0.662,
index; SI, stroke index computed as CI/HR; MAP, systemic mean arterial
resistance
Fig. 3 Evolution of metabolic variables during the experiment. T-60 min is the beginning of stabilization; T 0 min is the time of bacterial injection.
Esmolol is started and hemodynamic stabilization occurs between T 120 and T 180 min, and the experiment concluded at T 300 min. ANOVA
were performed for each parameter: (a) Lactate, group effect P = 0.486, time effect P = 0.117, time/group effect P = 0.398; (b) O2ERvar, group effect
P = 0.026, time effect P = 0.203, time/group effect P = 0.423; (c) VO2var, group effect P = 0.710, time effect P <0.001, time/group effect P = 0.510;
(d) DO2var, group effect P = 0.823, time effect P = 0.062, time/group effect P = 0.470. DO2, VO2, O2ER and lactate are expressed as variation
(variation are computed as tx divided by tbaseline). Lactate.var, lactate variation, O2ERvar, oxygen extraction ratio computed as the difference
between arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation, VO2var, oxygen consumption,
DO2var, oxygen delivery
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not find a significant correlation between videomicroscopy
parameters and GMLDF.
Effect of esmolol on resuscitation requirements
The effect of esmolol on resuscitation requirements are
shown in Table 3. A trend toward a greater amount of
resuscitation was observed with more fluid in the E
group, but these results were not significant (P = 0.093).
A significantly greater amount of milrinone was admin-
istered in the E group, but only one piglet required this
drug to fulfill the resuscitation criteria.Fig. 4 Evolution of gut microcirculation variables during the experiment. T-
injection. Esmolol is started and hemodynamic stabilization occurs betwee
concluded at T 300 min. ANOVA were performed for each parameter: resul
for the ratio of perfused villi. No significant effect was found for (b) MFI gu
of perfused villi under the number of villi visible on the stabilized video; MFI g
of the ileal mucosa computed as the difference between the highest and low
GMLDF, Gut microcirculatory laser Doppler blood flowDiscussion
In our experimental model of septic shock, esmolol ad-
ministration induced a significant decrease in HR and a
trend towards a decrease in CI and MAP. In contrast to
these macrocirculatory effects, esmolol did not alter sub-
lingual and gut microcirculation; conversely, a small im-
provement of some of the microcirculatory parameters
was observed.
The use of beta-blockers during septic shock has been
associated with a decreased mortality [1], but the reasons
for this remain to be elucidated. Among their potential in-
teresting effects, beta-blockers have been associated with a60 min is the beginning of stabilization; T 0 min is the time of bacterial
n T 60 and T 180 min after resuscitation is started, and the experiment
ts are detailed in Table 2. (a) A significant time/group effect was found
t or (c) heterogeneity.gut. PV, perfused villi ratio is defined as the ratio
ut, Mean Flow Index of the ileal mucosa; heterogeneity.gut, heterogeneity
est MFI, divided by the mean MFI of all sites at a single time point;
Table 2 Effect of esmolol on microcirculation of the E group compared to the C group
Time −60 min 60 min 270 min Group effect Time effect Time/group
effect
Group Control Esmolol Control Esmolol Control Esmolol P value P value P value
Gut
MFI of the gut 2.6 (2.5 - 2.9) 2.8 (2.5 - 2.9) 1.5 (1.3 - 1.6) 1.8 (1.4 - 1.8) 1.1 (0.8 - 1.7) 2 (1.7 - 2.1) 0.129 <0.001 0.200
Ratio of perfused villi 0.9 (0.8 - 1) 1 (0.9 - 1) 0.7 (0.6 - 0.7) 0.7 (0.6 - 0.8) 0.5 (0.4 - 0.7) 0.8 (0.8 - 0.9) 0.006 <0.001 0.025
Heterogeneity index
of the gut
10.3 (3 - 8.7) 18.8 (11.4 - 26.1) 68.6 (35.4 - 86.9) 48.6 (31.4 - 67.9) 81.8 (60 - 136.4) 73.5 (61.3 - 78) 0.267 0.001 0.376
Sublingual
TVD (n⋅mm) 18 (17.6 - 18.3) 16.1 (14.9 - 17.8) 12,9 (11,7 - 14,2) 11.4 (11.1 - 11.8) 15.9 (14.7 - 17) 15.9 (15.6 - 15.6) 0.270 0.822 0.931
TVD small vessels
(n⋅mm)
14.7 (14.2 - 15.6) 12.3 (12.3 - 12.6) 11.8 (11.1 - 13.7) 10.3 (9.8 - 11.5) 12.8 (12.1 - 14.3) 12.2 (12.1 - 13.7) 0.074 0.262 0.141
TVD other vessels
(n⋅mm)
2.4 (2 - 3) 3.4 (2.4 - 4.4) 0,6 (0,5 - 1,3) 1.0 (0.8 - 1.2) 2.5 (2 - 2.9) 3 (2.2 - 3.4) 0.022 0.074 0.151
PPV small vessels 94.1 (92.7 - 95.5) 87.3 (75.2 - 89.8) 63.7 (55.2 - 68.1) 64.6 (49.8 - 67.6) 75.5 (71.9 - 80.4) 77.5 (69.1 - 88.4) 0.568 0.183 0.212
PPV other vessels 100 (98.6 - 100) 98 (95.5 - 99.9) 92.7 (68.4 - 98.7) 98.5 (84.5 - 99.9) 97.4 (88.6 - 100) 96.8 (84.4 - 100) 0.772 0.63 0.757
MFI small vessels 2.8 (2.6 - 2.9) 2.7 (2.5 - 2.8) 1.7 (1.6 - 2.0) 1.5 (1.3 - 1.7) 2 (1.9 - 2.3) 2.1 (1.6 - 2.6) 0.528 0.07 0.542
MFI other vessels 3 (3 - 3) 2.9 (2.8 - 3) 2.8 (2.8 - 2.9) 2.9 (2.8 - 2.9) 2.8 (2.7 - 2.9) 2.8 (2.7 - 3) 0.552 0.051 0.491
Heterogeneity index 8.9 (4.4 - 17.1) 18 (6.5 - 26.8) 56.8 (38.6 - 97.4) 72.8 (37.8 - 78.9) 42 (29 - 60.7) 26.1 (18.2 - 33.5) 0.401 0.012 0.08
Gut microcirculatory parameters were performed on the ileal mucosa through a stoma. Sublingual microcirculation was measured at the base of the tongue. The cut-off value to differentiate small vessels and other
vessels is 20 μm. Density of vessel is performed by the De Backer score: six lines cross the image and three vertical and three horizontal vessels that cross the line are considered. The total of vessels crossing lines over
total line length shows the density of vessels
TVD, Total vessels density; MFI of the gut, Mean Flow Index of the ileal mucosa; MFI small vessels, sublingual Mean Flow Index of small vessels; MFI other vessels, Mean Flow Index of other vessels; Density small









Table 3 Drug and fluid administration in the esmolol and
control group
E group C group P value
Fluids (mL) 625 (500 - 938) 250 (250 - 438) 0.093
Norepinephrine (μg) 2130 (1469 - 2127) 1833 (1167 - 2250) 0.484
Esmolol (mg) 180 (160 - 1840) 0 (0 - 0) 0.003
Milrinone (mg) 0 (0 - 1.81) 0 (0 - 0) 0.016
E group, esmolol group; C group, control group
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disorders induced by sepsis [26]. Esmolol has also been
reported to prevent gut barrier dysfunction [12, 27], an ef-
fect that seems attractive as the gut is suspected to play a
major role in the sustainability of sepsis, with its dysfunc-
tion leading to multiple organ dysfunction syndrome [28].
The immunologic effect is unclear, but different studies
have reported a diminution of systemic inflammation and
a diminution of cytokines decompartmentalization [3].
Beta-blockers may also re-orientate cytokines from an
adrenergic-induced pro-inflammatory Th2-type profile to
an anti-inflammatory Th1-type profile [26, 29]. Esmolol
may also provide cardioprotective effects by improving
myocardial DO2 and cardiac output [2]. Finally, its short
half-life permits a better compliance of the treatment in a
context of circulatory failure [30]. Recently, this drug has
been reported to improve septic shock mortality in
humans [1].
In our experiment, microcirculatory impairments were
observed at the onset of shock. As an early resuscitation
was administered, we could not observe any lactate
elevation, prolonged hypotension or low cardiac output.
Even though the increase in CI and MAP were not sig-
nificant, the trends of these macrocirculatory parameters
(with a significant increase in HR) were in favor of
hyperdynamic shock. These cardiovascular modifications
were associated with a decrease in microcirculatory indexes.
Such an uncoupling of macro and microcirculation
during sepsis is consistent with the literature [31, 32],
and is associated with worsened outcome [17].
Esmolol was given after stabilization of macrocircula-
tory parameters. As expected, it produced a significant
decrease in HR, as well as a trend towards a significant
decrease of MAP and CI, and an increase in SVR. This
rise of SVR can be explained by the greater amount of
norepinephrine used in the E group, even though this
difference was not significant; it could also be the result
of a mathematical coupling between a decrease of CI and
a maintenance of MAP. Another explanation could be the
preservation of the vasoreactivity by esmolol. The effects
of esmolol on SVR are not consistent in the literature: it
has been reported to increase [1] or decrease SVR [33].
We did not observe any improvement in SI or CI in the
present study, and milrinone was used in only one pigletin the E group to fulfill the therapeutic target. This result
was unexpected as an increase in SI was anticipated, re-
lated to a better ventricular filling. In a non-resuscitated
rat model, an increase in SI was described and attributed
to an improvement of preload and a longer diastole [29].
Such an improvement was also found by Morelli et al.
in human patients, but an inotropic drug (levosimendan)
was administered in both treated and control groups [1].
The increased use of milrinone in our study was consist-
ent with a previous study using metoprolol [34] and
another study using atenolol, where no effect on SVR, CI
and oxygen consumption were reported [35]. We assume
that when enough fluid is administered for hemodynamic
resuscitation of sepsis, there is no preload dependency for
cardiac output, as predicted by the Frank-Starling law of
the heart. Thus, even if preload is increased by a longer
diastole, it does not necessarily increase cardiac output.
This could explain why our results are different from
other models of septic shock described in previous studies
where no fluid were administered [29].
No reduction of VO2 was observed in the E group,
which differs from the results of Morelli et al. [1], but is
consistent with a previous study performed on septic
piglets where the effect of esmolol was assessed earlier
during the time course of sepsis [33]. Considering its
potential microcirculatory recruitment, esmolol should
increase VO2; however, this effect is dampened by a de-
creased HR, cardiac oxygen consumption and hyper-
adrenergic cell catabolism, which may reduce VO2.
In our experiment, despite macrocirculation impair-
ment, we did not observe a significant alteration of micro-
circulation following esmolol administration. Conversely
to the control group, gut microcirculation parameters,
assessed with SDF, remained stable. Some of the gut
microcirculatory parameters improved in the E group.
The mechanisms of these positive effects on microcircu-
lation remain to be determined. The beta theory of shock
developed by Berk et al. [4] has never gained acceptance.
In this theory, treatment with beta-blockers may induce a
reduction of shunting and subsequent microcirculatory re-
cruitments. An increase in SI may also restore pulsatility
and reverse microcirculation impairment in near laminar
flow [36], as previously reported in some studies [1, 33].
This is not supported by our experimental data, as SI was
not increased in the E group. Other non-hemodynamic ef-
fects of beta-blockers can be considered: beta-1-selective
adrenergic receptor blockers have been reported to in-
crease endothelial NO production, which may facilitate
microcirculation recruitment [37]. A fibrinolytic activity
may also dampen the pro-coagulant state induced by sep-
sis [38], and prevent microcirculation impairment related
to microthrombi formation [39].
Evaluation of correlation between gut and sublingual
microcirculation was not the principal aim of our study,
Jacquet-Lagrèze et al. Critical Care  (2015) 19:241 Page 9 of 11and we report no correlation between both microcircula-
tions in our experimental setting, which remains consist-
ent with the conflicting reports in the literature regarding
the link between both sites [40, 41]. Nevertheless, micro-
circulatory evolution trends appeared quite similar be-
tween both sites in our data.
We acknowledge some limitations to our study. First,
our model of septic shock did not meet all the criteria of
hyperdynamic shock, as there was only a trend toward
significance for the observed increase in CI. This could
be due to a lack of statistical power due to the small
sample size. Second, we noticed a difference between
both groups at baseline for some variables, which may
also be attributed to the small sampling size of our
experimental setting. Weight and body surface area were
different between groups: even though these differences
were statistically significant, they were not considered
clinically relevant as the difference was only 1.7 kg. This
difference was also minimized by the fact that all data
was indexed by body weight or by body surface area.
Third, SvO2 appeared different between both groups.
Even if there was a significant group effect, it does not
seem relevant as all data remained in normal ranges.
Moreover, no time/group effect was found, which is in
favor of an absence of effect of esmolol on SvO2 evolu-
tion. The conclusion that we drew on DO2 and con-
sumption is hampered by the fact that our method of
calculation of these parameters may be biased due to
mathematical coupling of the data. Calorimetry could
have been used as an alternative method, but its
utilization is cumbersome, with its own limitations [42].
Fourth, we observed a slight elevation of lactate and a
slight impairment of microcirculation at the beginning
of the experiment, followed by a normalization during
the stabilization period. This may be explained by surgi-
cal preparation [43], induction of anaesthesia before
endotracheal intubation or drugs used for anesthesia
induction [44]. Fifth, the lack of correlation between
laser Doppler and videomicroscopy was unexpected, but
may be explained by the fact that the sampling depth of
the laser Doppler signal is much deeper compared with
videomicroscopy. A large part of the laser Doppler signal
is thus related to the arteriolar component. Only a small
component of microcirculation with vessels less than
20 μm (which are analyzed in the villi) seemed to be in-
fluenced by sepsis. Thus, any effect of esmolol may have
been dampened with laser Doppler technology. To our
knowledge, videomicroscopy and laser Doppler have not
been formally compared. Sixth, we did not assess organ
dysfunction and survival to sepsis, but the study was not
designed for this purpose. We cannot exclude that the
better microcirculation observed in the E group may be
related to the greater amount of fluids and positive ino-
tropes and/or norepinephrine administered, even thoughthe differences between groups were not significant. An
increased administration of fluids has been reported to
enhance microcirculation at the early phase of sepsis
[45]. Finally, the dose of esmolol used and the target
chosen may have been too aggressive and could also
partially explain the negative effect on CI, which was not
observed in previous studies. However, there is not enough
data in the literature to evaluate the suitable doses and
targets. The introduction of esmolol occurred very early in
the course of sepsis compared to other studies, and we do
not know if the effects of esmolol observed in our experi-
mental conditions are sustainable for a longer period.
Conclusions
Esmolol provided a maintenance of microcirculation during
sepsis despite its effects on macrocirculation. Some of our
data suggest an improvement in gut microcirculation. A
trend towards a decrease in CI and DO2 was observed
following esmolol administration, but lactate and VO2 were
not significantly altered. These results provide a better
understanding of the hemodynamic and microcirculatory
effects of beta-blockers during sepsis, with a decreased
uncoupling between microcirculation and macrocircula-
tion, even though the mechanism of action remains to be
elucidated. The fear of a negative microcirculatory effect of
esmolol is not supported by our data, but this treatment
should be carefully developed in the time course of sepsis.
In addition to macrocirculation monitoring, assessing
microcirculation could be an interesting guide to evaluating
the appropriate dosage and timing of administration of
esmolol.
Key messages
Esmolol allowed better maintenance of gut microcircula-
tion despite a reduction of stroke index in a resuscitated
piglet model of septic shock.
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